These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 26075238)

  • 1. Physicochemical and biological characterization of a biosimilar trastuzumab.
    López-Morales CA; Miranda-Hernández MP; Juárez-Bayardo LC; Ramírez-Ibáñez ND; Romero-Díaz AJ; Piña-Lara N; Campos-García VR; Pérez NO; Flores-Ortiz LF; Medina-Rivero E
    Biomed Res Int; 2015; 2015():427235. PubMed ID: 26075238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate.
    Chen L; Wang L; Shion H; Yu C; Yu YQ; Zhu L; Li M; Chen W; Gao K
    MAbs; 2016 Oct; 8(7):1210-1223. PubMed ID: 27380163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic Comparability of a Biosimilar Trastuzumab Anticipated from Its Physicochemical and Biological Characterization.
    Miranda-Hernández MP; López-Morales CA; Piña-Lara N; Perdomo-Abúndez FC; Pérez NO; Revilla-Beltri J; Molina-Pérez A; Estrada-Marín L; Flores-Ortiz LF; Ruiz-Argüelles A; Medina-Rivero E
    Biomed Res Int; 2015; 2015():874916. PubMed ID: 26682224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study.
    Joshi S; Rathore AS
    BioDrugs; 2020 Apr; 34(2):209-223. PubMed ID: 31975160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment.
    Lee JH; Paek K; Moon JH; Ham S; Song J; Kim S
    BioDrugs; 2019 Aug; 33(4):411-422. PubMed ID: 31190280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.
    Lee J; Kang HA; Bae JS; Kim KD; Lee KH; Lim KJ; Choo MJ; Chang SJ
    MAbs; 2018; 10(4):547-571. PubMed ID: 29482416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.
    Markus R; Liu J; Ramchandani M; Landa D; Born T; Kaur P
    BioDrugs; 2017 Jun; 31(3):175-187. PubMed ID: 28439817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar.
    Kim S; Song J; Park S; Ham S; Paek K; Kang M; Chae Y; Seo H; Kim HC; Flores M
    MAbs; 2017; 9(4):704-714. PubMed ID: 28296619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytic characterization of biosimilars.
    Sullivan PM; DiGrazia LM
    Am J Health Syst Pharm; 2017 Apr; 74(8):568-579. PubMed ID: 28389456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of biosimilars.
    Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab.
    Hutterer KM; Polozova A; Kuhns S; McBride HJ; Cao X; Liu J
    BioDrugs; 2019 Jun; 33(3):321-333. PubMed ID: 30972630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.
    Sörgel F; Schwebig A; Holzmann J; Prasch S; Singh P; Kinzig M
    BioDrugs; 2015 Apr; 29(2):123-31. PubMed ID: 25837839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies.
    Ishii-Watabe A; Kuwabara T
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):64-70. PubMed ID: 30600193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab).
    Hong J; Lee Y; Lee C; Eo S; Kim S; Lee N; Park J; Park S; Seo D; Jeong M; Lee Y; Yeon S; Bou-Assaf G; Sosic Z; Zhang W; Jaquez O
    MAbs; 2017; 9(2):364-382. PubMed ID: 28005456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of pharmacometrics to optimize biosimilar development.
    Dodds M; Chow V; Markus R; Pérez-Ruixo JJ; Shen D; Gibbs M
    J Pharm Sci; 2013 Nov; 102(11):3908-14. PubMed ID: 24027111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab.
    Jassem S; Wang W; Sweet H; Manoukian R; Chow V; Kanakaraj P; Hutterer KM; Kuhns S; Foltz IN; Chen Q; Ferbas J; McBride HJ
    Pharm Res; 2019 Nov; 36(12):177. PubMed ID: 31696314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept.
    Cho IH; Lee N; Song D; Jung SY; Bou-Assaf G; Sosic Z; Zhang W; Lyubarskaya Y
    MAbs; 2016; 8(6):1136-55. PubMed ID: 27246928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
    Kim WS; Coiffier B; Kwon HC; Kim S
    Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA's Approach to Regulating Biosimilars.
    Lemery SJ; Ricci MS; Keegan P; McKee AE; Pazdur R
    Clin Cancer Res; 2017 Apr; 23(8):1882-1885. PubMed ID: 28034906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing clinical trials for biosimilars.
    Bui LA; Taylor C
    Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.